Care Oncology

Question/ Intervention Goal/ Objectives

Breast and prostate cancer patients who take statins and/or metformin tend to have lower rates of death. Since cancer patients’ expenses are highest at initial diagnosis and at end-of-life1, a lower mortality rate can reduce medical costs for payers. In addition, statins have been shown to reduce the five-year breast cancer recurrence rate; having fewer patients experience recurrence would also lower medical costs.
Care Oncology Clinics use a patented combination of low-cost, low side-effect drugs, which have been shown to improve cancer treatment outcomes. The medications are in addition to and do not alter the patient’s cancer treatment.

This validation uses previously published research and focuses on two cancers that are common in working-age populations: breast and prostate.

Method/ Calculation

A nationwide cohort study of women with breast cancer stratified women by whether they were taking a statin drug. The breast-cancer-specific mortality rate was compared between the two groups.

A meta-analysis combined data from three studies of recurrence free survival among breast cancer patients, stratified by whether and what type of statin medication they were taking.

A population-based retrospective cohort study merged data from public health data sets on prostate cancer patients. The mortality rate for patients who had taken a statin alone or in combination with metformin was compared to patients who had neither drug.

Findings/ Metric/ Outcome/ Savings

The breast cancer cohort study found that patients taking a statin had a 16% lower rate of breast-cancer-specific death than patients not taking a statin.

The meta-analysis found a 12% lower five-year breast cancer recurrence rate for patients taking lipophilic statins.

The prostate cancer patients who took a statin alone or in combination with metformin had 11% lower rate of death overall, and a 20% lower rate of death from prostate cancer than patients who took neither drug.


Though the impact of the intervention on cancer mortality rate is well established in literature, the impact on a payer’s medical costs is not yet demonstrated.